Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol plus PD-1–based regimen after first-line PD-1 failure in unresectable HCC with vitamin D deficiency
ChiCTR2500113259Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paricalcitol in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Progression-Free Survival, Objective Response Rate and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
paricalcitol
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500113259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113259.